Intercept Pharmaceuticals (NAS:ICPT) Pretax Margin %

: -46.91% (As of Mar. 2023)

View and export this data going back to 2012. Start your Free Trial

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Intercept Pharmaceuticals's Pre-Tax Income for the three months ended in Mar. 2023 was $-31.9 Mil. Intercept Pharmaceuticals's Revenue for the three months ended in Mar. 2023 was $68.0 Mil. Therefore, Intercept Pharmaceuticals's pretax margin for the quarter that ended in Mar. 2023 was -46.91%.

The historical rank and industry rank for Intercept Pharmaceuticals's Pretax Margin % or its related term are showing as below:

ICPT' s Pretax Margin % Range Over the Past 10 Years
Min: -16258.67 Med: -223.59 Max: -52.29
Current: -58.84

ICPT's Pretax Margin % is ranked better than
62.66% of 1023 companies
in the Biotechnology industry
Industry Median: -195.63 vs ICPT: -58.84

Intercept Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for Intercept Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Pretax Margin %

-171.99

-136.78

-116.85

-52.29

-61.20

Intercept Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Pretax Margin %																-56.53	-28.32	-134.15	-22.02	-46.91

Intercept Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Intercept Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-174.858	/	285.71
	=	-61.20 %

Intercept Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Mar. 2023 )	/	Revenue (Q: Mar. 2023 )
	=	-31.881	/	67.958
	=	-46.91 %

Intercept Pharmaceuticals (NAS:ICPT) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Intercept Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (NAS:ICPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

I4P:Germany

Address

10 Hudson Yards, 37th Floor, New York, NY, USA, 10001

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Executives

Andrew Saik	officer: EVP & Chief Financial Officer	640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey	officer: President, R&D and CMO	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia	officer: Chief Accounting Officer	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Lisa Defrancesco	officer: SVP, IR & Corp. Affairs	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson	officer: EVP & Chief Commercial Officer	2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg	officer: General Counsel and Secretary	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paolo Fundaro	director, 10 percent owner	C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener	director	900 FIFTH AVENUE, #8C, NEW YORK NY 10021
Luca Benatti	director	C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451